Literature DB >> 181558

Regulation of cyclic nucleotide levels and glycogen phosphorylase activity by acetylcholine and epinephrine in perfused rat hearts.

R M Gardner, D O Allen.   

Abstract

Acetylcholine (ACh) produced a time and dose-dependent increase in cyclic 3',5'-guanosine monophosphate (cyclic GMP) levels in perfused rat hearts without any significant (P greater than .05) change in cyclic 3',5'-adensoine monophosphate (cyclic AMP) level or glycogen phosphorylase activity. Epinephrine produced a dose-dependent increase in both cyclin AMP and phosphorylase activity but no significant (P greater than .05) change in cyclic GMP levels. When ACh (10(-6) M) was infused into hearts during the infusion of epinephrine (10(-6) M), a time-dependent increase in cyclic GMP and decrease in cyclic AMP occurred, both of which preceded a significant (P less than .05) decrease in glycogen phosphorylase activity. In epinephrine-stimulated hearts, ACh produced a dose-dependent increase in cyclic GMP levels. Similar concentrations produced a fall in cyclic AMP levels and phosphorylase activity. No condition tested resulted in a significant (P greater than .05) change in glycogen synthase activity. It is concluded that ACh can reduce cyclic AMP levels and phosphorylase activity only when they have been elevated above basal values. These changes are associated with an increase in cyclic GMP. The reduction in phosphorylase produced by ACh may be the result of either or both of the changes in cyclic nucleotide levels.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 181558

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Effects of papaverine and its interaction with isoprenaline and carbachol on the contractile force and cyclic nucleotide levels of the canine ventricular myocardium.

Authors:  M Endoh; M Honma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

2.  Activation of hormone-sensitive lipase and phosphorylase kinase by purified cyclic GMP-dependent protein kinase.

Authors:  J C Khoo; P J Sperry; G N Gill; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

3.  Sensitivity to cyclic nucleotides and to aspirin of the kininogen-consuming system activated by adrenaline or carbamylcholine in rat blood.

Authors:  A M Rothschild; A Castania
Journal:  Agents Actions       Date:  1978-01

4.  The time course of changes in cyclic nucleotide levels during cholinergic inhibition of positive inotropic actions of isoprenaline and theophylline in the isolated canine ventricular myocardium.

Authors:  M Endoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

5.  Muscarinic receptor stimulation and cyclic AMP-dependent effects in guinea-pig ventricular myocardium.

Authors:  R Schmied; M Korth
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

6.  Characteristics of histamine release evoked by acetylcholine in isolated rat mast cells.

Authors:  P Blandina; R Fantozzi; P F Mannaioni; E Masini
Journal:  J Physiol       Date:  1980-04       Impact factor: 5.182

7.  Muscarinic-cholinoceptor mediated attenuation of phospholamban phosphorylation induced by inhibition of phosphodiesterase in ventricular cardiomyocytes: evidence against a cAMP-dependent effect.

Authors:  R C Gupta; J Neumann; A M Watanabe; H N Sabbah
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

8.  Are acetylcholine-induced increases in 42K efflux mediated by intracellular cyclic GMP in turtle cardiac pace-maker tissue?

Authors:  B P Fleming; W Giles; J Lederer
Journal:  J Physiol       Date:  1981-05       Impact factor: 5.182

9.  Differential responses to carbachol, sodium nitroprusside and 8-bromo-guanosine 3',5'-monophosphate of canine atrial and ventricular muscle.

Authors:  M Endoh; S Yamashita
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.